Abstract
Genomic analysis of pancreatic cancer and other solid tumors has revealed that cancer is a proteomic network disease at the functional level. Protein pathway activation is measured by posttranslational modifications such as phosphorylation that control cellular signaling, and these events are not effectively measured by DNA or RNA analysis alone. In fact, these signaling pathways represent the targets for the molecularly targeted therapeutics, and so it is critical that we begin to define human cancer at a functional pathway activation level. Reverse phase protein microarrays is a key enabling new technology that can generate a functional map of activated protein networks directly from a biopsy specimen. This patient-specific "circuit diagram" provides key information for individualized therapy and can be integrated into a multi-omic systems-level portrait of genomic-to-proteomic information content. The identification of activated protein drug target networks in pancreatic tumors can then be used for drug selection and patient stratification wherein the activated protein "circuit diagram" becomes the ultimate companion diagnostic assay for systems medicine.
Original language | English |
---|---|
Title of host publication | Molecular Diagnostics and Treatment of Pancreatic Cancer |
Publisher | Elsevier Inc. |
Pages | 367-383 |
Number of pages | 17 |
ISBN (Print) | 9780124081031 |
DOIs | |
State | Published - Apr 2014 |
Externally published | Yes |
Keywords
- Biomarkers
- Cell signaling
- Companion diagnostics
- Oncology
- Pancreatic cancer
- Pathway mapping
- Personalized therapy
- Phosphoprotein